Clinical potential of PD-1/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy

Clinical potential of PD-1/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy

Abstract Programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) blockade therapy has become a game-changing therapeutic approach revolutionizing the treatment setting of human malignancies, such as renal cell carcinoma (RCC). Despite the remarkable clinical activity of anti-PD-1 or anti-PD-L1 m...

Full description

Bibliographic Details
Main Authors: Mohammadsaleh Jahangir, Omid Yazdani, Mohammad Saeed Kahrizi, Sara Soltanzadeh, Hamidreza Javididashtbayaz, Azam Mivefroshan, Saba Ilkhani, Romina Esbati
Format: Article
Language:English
Published: BMC 2022-12-01
Series:Cancer Cell International
Subjects:
Programmed death-1 (PD-1)
Programmed death-ligand 1 (PD-L1)
Renal cell carcinoma (RCC)
Combination therapy
Resistance
Online Access:https://doi.org/10.1186/s12935-022-02816-3

Internet

https://doi.org/10.1186/s12935-022-02816-3

Similar Items